ERBB2 and triple-negative breast carcinoma: Although endocrine-responsive breast cancer patients (ERBC) generally have a better outcome than human epidermal growth factor receptor-2 (HER2)-enriched and triple negative breast cancer patients (TNBC), the risk of long-term disease recurrence is unpredictable (1).